NCT04007133 (DIOS) is a clinical trial of Girerd test in Non-insulin-dependent Diabetes, sponsored by Lille Catholic University.

Who is sponsoring NCT04007133?

NCT04007133 is sponsored by Lille Catholic University.

What drugs are being tested in NCT04007133?

Interventions in NCT04007133: Girerd test.

What condition does NCT04007133 study?

NCT04007133 studies Non-insulin-dependent Diabetes.

Is NCT04007133 still recruiting?

NCT04007133 is currently terminated. Last updated 17 July 2019.

Last reviewed 2019-07-17 · How we verify

NCT04007133: DIOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Statin Compliance of Patients With Non-insulin-dependent Diabetes

Terminated Last updated 17 July 2019

What this trial tests

trial testing Girerd test in Non-insulin-dependent Diabetes in 119 participants. Terminated before completion.

Timeline

31 January 2018

Primary endpoint
12 July 2018

12 July 2018

Quick facts

Lead sponsor	Lille Catholic University
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	119
Start date	31 January 2018
Primary completion	12 July 2018
Estimated completion	12 July 2018
Sites	1 location across France

Drugs / interventions tested

Girerd test

Conditions studied

Non-insulin-dependent Diabetes — all drugs for Non-insulin-dependent Diabetes →

Sponsor

Lille Catholic University

Who can join

18 and older, any sex, with Non-insulin-dependent Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The diabetic population has an increased cardiovascular risk compared to the general population. Hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase) inhibitors, or "statins", are considered as the standard treatment for hypercholesterolemia. Many patients with non-insulin-dependent diabetes are prescribed with statins, both for primary prevention, before the first cardiovascular event, and as secondary prevention, to avoid recurrence. However, compliance to these drugs may be difficult due to polypharmacy, side effects (myalgia) or tiredness. The purpose of this study is to determine the compliance of diabetic patients with statins searching for important factors which could favor adherence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Lille Catholic University trials

Trials by the same sponsor.

NCT06634225 — Use of Inertial Units in Patient With Multiple Sclerosis (IMUSEP) · completed
NCT06116929 — Hodgkin's Disease and Chemotherapy Before 40 Years · NA · not yet recruiting
NCT05208099 — Study of the Immunomodulation in the Hidradenitis Suppurativa and Evaluation of a New Therapeutic Strategy · not yet recruiting
NCT06318923 — Social and Moral Cognition in Multiple Sclerosis · NA · unknown
NCT06083415 — Early Breast Growth in Girls Aged 6 to 8 Years in the Current Environmental Context · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04007133 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lille Catholic University
Last refreshed: 17 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04007133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing